Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 05/21/18
End: 03/30/20
Due: 03/30/21
Phase: N/A
Priority: Normal
Start: 09/02/22
End: 12/30/24
Due: 12/30/25
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Study of the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Antitumor Activity of KN046 in Subjects With Advanced Solid Tumors | NCT03529526 | Alphamab (Australia) Co Pty Ltd. | user2@example.com | None | 2018-05-21 | 2020-03-30 | 2021-03-30 | - | - | 2025-07-14 |
| First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors | NCT05494918 | Alphamab (Australia) Co Pty Ltd. | user2@example.com | None | 2022-09-02 | 2024-12-30 | 2025-12-30 | - | - | 2025-07-14 |